abrdn Life Sciences Investors
HQL
49 hedge funds and large institutions have $43.8M invested in abrdn Life Sciences Investors in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 5 closing their positions.
229% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 7
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
9% more funds holding
Funds holding: 45 → 49 (+4)
8% more capital invested
Capital invested by funds: $40.7M → $43.8M (+$3.1M)
2.04% more ownership
Funds ownership: 11.24% → 13.28% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$1.28M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$1.01M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$852K |
| 4 |
Cohen & Steers
New York
|
+$717K |
| 5 |
AGM
Alpine Global Management
New York
|
+$451K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
Doliver Advisors
Houston,
Texas
|
-$573K |
| 2 |
AAM
Advisors Asset Management
Monument,
Colorado
|
-$452K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$404K |
| 4 |
UR
USCA RIA
Houston,
Texas
|
-$335K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$290K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| – | +$70 | +4 | New |
|
52
JP Morgan Chase
New York
| – | +$351 | +20 | New |
|
HQL Hedge Fund Activity: Q4 2016 in Review
49 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2016, worth a combined $43.8M — up 7.6% from $40.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new HQL positions and 5 closed out — a net gain of 5 holders — while 23 added to existing stakes and 7 trimmed.
The largest buyer was Citigroup, adding an estimated $1.28M. The largest seller was Doliver Advisors, cutting an estimated $573K.
- 49 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2016, up from 45 in Q3 2016.
- Funds reported $43.8M of abrdn Life Sciences Investors stock for Q4 2016, up 7.6% quarter-over-quarter.
- 10 funds opened new abrdn Life Sciences Investors positions in Q4 2016 and 5 closed out, a net change of +5 holders.
- The largest abrdn Life Sciences Investors buyer in Q4 2016 was Citigroup, an estimated $1.28M added.
- The largest abrdn Life Sciences Investors seller in Q4 2016 was Doliver Advisors, an estimated $573K sold.
Based on aggregated 13F filings for Q4 2016.